Insider Selling: Bioventus Inc. (NYSE:BVS) SVP Sells $22,392.06 in Stock

Bioventus Inc. (NYSE:BVS) SVP Anthony D’adamio sold 2,958 shares of the business’s stock in a transaction that occurred on Friday, April 11th. The shares were sold at an average price of $7.57, for a total transaction of $22,392.06. Following the transaction, the senior vice president now owns 131,416 shares of the company’s stock, valued at approximately $994,819.12. This represents a 2.20 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Anthony D’adamio also recently made the following trade(s):

• On Tuesday, February 18th, Anthony D’adamio sold 4,380 shares of Bioventus stock. The shares were sold at an average price of $10.19, for a total value of $44,632.20.

Bioventus Price Performance

Shares of NYSE:BVS opened at $7.82 on Friday. Bioventus Inc. has a one year low of $3.90 and a one year high of $14.38. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.41 and a quick ratio of 0.99. The company has a market cap of $640.80 million, a price-to-earnings ratio of -12.82 and a beta of 0.92. The firm has a 50 day simple moving average of $9.35 and a 200 day simple moving average of $10.63.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in Bioventus by 18.7% in the 4th quarter. Vanguard Group Inc. now owns 2,462,081 shares of the company’s stock worth $25,852,000 after purchasing an additional 388,174 shares in the last quarter. Driehaus Capital Management LLC grew its holdings in shares of Bioventus by 33.7% during the fourth quarter. Driehaus Capital Management LLC now owns 1,119,855 shares of the company’s stock worth $11,758,000 after purchasing an additional 282,341 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Bioventus by 7.5% in the third quarter. Geode Capital Management LLC now owns 940,496 shares of the company’s stock valued at $11,241,000 after buying an additional 65,374 shares during the period. American Century Companies Inc. raised its holdings in Bioventus by 38.7% in the 4th quarter. American Century Companies Inc. now owns 884,673 shares of the company’s stock valued at $9,289,000 after buying an additional 246,645 shares during the last quarter. Finally, Nuveen Asset Management LLC boosted its position in Bioventus by 20.9% during the 4th quarter. Nuveen Asset Management LLC now owns 782,137 shares of the company’s stock worth $8,212,000 after buying an additional 135,236 shares during the period. 62.94% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Bioventus in a research note on Monday, March 17th.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.